Link to coporate website: http://www.transgenomic.com/ TICKER SYMBOL:TBIO Share Structure | Market Value1 | $40,142,705 | a/o May 10, 2013 |
| Shares Outstanding | 88,225,725 | a/o Mar 13, 2013 |
| Float | Not Available |
| Authorized Shares | 100,000,000 | a/o Aug 02, 2011 |
| Par Value | 0.01 |
TRANSFER AGENT: Wells Fargo Bank Minnesota, N.A.
Shareowner Services
P.O. Box 64854
St. Paul, MN 55164-0854
Phone: 877-602-7611
About: Transgenomic is a global biotechnology company that provides unique products and services for automated high sensitivity genetic variation and mutation analysis. Our offerings include systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of pharmacogenomics and personalized medicine.
Transgenomic offers its WAVE® DHPLC Systems and associated consumables. These systems are specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification and have broad applicability to genetic research. To date there have been over 1600 systems shipped to more than 30 countries.
Transgenomic's SURVEYOR® Mutation Detection Kits and the SURVEYOR Check-It Kit provide reagents and protocols for the detection of mutations in DNA.
Transgenomic's Cytogenetics offering includes HANABI automated chromosome harvesting systems that improve laboratory productivity with consistent quality compared to manual methods.
Transgenomic Clinical Reference Laboratory provides reference laboratory services specializing in molecular diagnostics including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology and Inherited Diseases.
Transgenomic Genomic Research Services is a CRO for pharmacogenomic, translational research and clinical trials.
Colorectal Cancer Testing
Very important AMGEN signs collaberation deal with Mgmt:
"Another potential meaningful near-term contributor to the Lab Services segment (as well as to the Diagnostic Tools segment) relates to the recently consummated agreement with Amgen (NasdaqGS:AMGN) whereby the two companies are collaborating on a KRAS an NRAS gene mutation assay kit to screen patients for colorectal cancer. The RAScan test is currently available for research use only (RUO) in the U.S. (which will run through Lab Svcs) and for clinical use in Europe - which could help accelerate instrument placements (through Menarini) as well as increase consumables sales"
CRC RAScan™ is a new mutation detection test designed to screen for selected KRAS and NRAS mutations (collectively referred to as “RAS mutations”), in patients with metastatic colorectal cancer (mCRC).The identification of these RAS mutations can give physicians important clinical information to help them make better treatment decisions for their mCRC patients.
KRAS and NRAS are part of the RAS family of genes which encode proteins involved in transmitting signals within cells. When Ras proteins are “switched on” by incoming signals, other genes involved in cell growth, differentiation, and survival are activated. Mutations in KRAS, NRAS and other related genes can lead to Ras proteins becoming permanently activated, causing overactive signaling even in the absence of incoming signals, and can lead to the uncontrolled cell growth that characterizes cancer. Mutations that permanently activate Ras proteins are found in ~25% of human tumors and up to 90% of certain cancers. About 40% of colorectal tumors carry KRAS gene mutations and these mutations have been associated with poor response to EGFR antagonists such as cetuximab and panitumumab. Therefore KRAS mutation status can be used to determine whether or not a patient with colorectal cancer will respond to anti-EGFR therapy.
The CRC RAScan test can identify mCRC patients who have RAS mutations at levels that cannot be detected using traditional Sanger Sequencing methods.
CRC RAScan™ for Colorectal Cancer Tumor Testing is available immediately from Transgenomic’s CLIA-certified laboratory in the United States. For more information on this test, click here.
CRC RAScan Mutation Detection Kits will soon be available in the U.S for research use only. CRC RAScan Mutation Detection Kits include the following kits based on Transgenomic's proprietary SURVEYOR® Nuclease technology:
- KRAS Exon 2
- KRAS Exons 3 & 4
- NRAS Exons 2, 3 & 4
Zacks analyst ~ OUR 2013 OUTLOOK~ We've again made some updates to our model. We now model 2013 revenue of $32.4 million, implying growth of 3% from 2012. We look for Laboratory Services and Instruments to generate revenue of $20.0 million (+4%) and $12.4 million (+2%), respectively. We think net income and EPS come in at ($12.7) million and ($0.14). 2013 ASCO CONFERENCE ABSTRACT http://www.amgen.com/media/media_pr_detail.jsp?year=2013&releaseID=1820728 May. 15, 2013 AMGEN PRESS RELEASE
Contact Information: Phone: (402) 452-5437
E-mail: investorrelations@transgenomic.com
SEC Filings: http://www.nasdaq.com/asp/quotes_sec.asp?page=filings&symbol=TBIO&selected=TBIO&rpage=sec& 
Press Releases: http://finance.yahoo.com/q?s=TBIO.OB 
